Solid Lipid Curcumin Particle (SLCP) Discussion Paper

Committee Paper for Discussion - ACNFP/171/04

Advisory Committee For Novel Foods and Processes

Application for authorisation as a novel food for Solid Lipid Curcumin Particle (SLCP)

Application Number - RP1776

Issue

An application has been received under the novel food authorisation process (assimilated Regulation 2015/2283) for solid lipid curcumin particle (SLCP). The Committee is asked to advise on whether the available data provides an adequate basis for a risk assessment, and whether the novel food is safe and not nutritionally disadvantageous under the proposed uses and use levels.

A draft Committee Advice Document (CAD) has been prepared to support the review of this novel food application. Members are asked to consider the CAD and provide comments.

Background

1. On the 24th October 2022  , the FSA received the submission for solid lipid curcumin particle (SLCP), from Verdure Sciences, USA.

2. The novel food is SLCP which is manufactured from a solvent extract of curcumin (Curcuma longa L.) rhizomes and blended with other food grade ingredients. The applicant intends to use the novel food in food supplements for adults only, at use levels up to 500 mg/day.

3. The draft CAD is attached as Annex A. The application dossier and the annexes to the dossier are attached as Annexes B and C, respectively. These contain confidential information. The FSA’s request for further information (RFI) and the applicant’s response to the RFI are included as Annexes D and E, respectively. Annex E also contains confidential information.

Committee Action Required

• The Committee is asked whether the available data provide a satisfactory basis for evaluating the safety of the novel food under the proposed uses.
• If so, the Committee is asked whether it is content to recommend approval of the novel food as an ingredient to be added to the range of foods specified.
• If not, the Committee is asked to indicate what additional data would be required.

ACNFP Secretariat

April 2025

Annexes 

ACNFP-171-04-Annex A – Draft Committee Advice Document 

ACNFP-171-04-Annex B – Dossier and References [Confidential]

ACNFP-171-04-Annex C – Annexes [Confidential]

ACNFP-171-04-Annex D – Request for Information

ACNFP-171-04-Annex E – Response to Request for Information